Orphan drug pricing and payer management in the United States: are we approaching the tipping point?

@article{Hyde2010OrphanDP,
  title={Orphan drug pricing and payer management in the United States: are we approaching the tipping point?},
  author={Rebecca Hyde and Diana Dobrovolny},
  journal={American health & drug benefits},
  year={2010},
  volume={3 1},
  pages={15-23}
}
The Orphan Drug Act of 1983 paved the way for the development of drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients. Orphan drugs can cost hundreds of thousands of dollars annually, but insurers have traditionally covered these therapies because the small populations involved did not typically lead to significant cost exposure. Payer sensitivity to the cost of orphan drugs is rising, however, with the accelerated rate of new launches of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

References

Publications referenced by this paper.

OPPS payment changes for drugs , biologicals , and radiopharmaceuticals

  • MC Haren, K McConnell
  • Fed Regist
  • 2008

Similar Papers

Loading similar papers…